(Alliance News) - Genflow Biosciences PLC on Thursday said its collaborative partners, which include University of Rochester, Columbia University and Albert Einstein College of Medicine, have received confirmation that their European patent application has been approved for SIRT6.
The London-based biotechnology company focused on longevity said the patent application was published today by the European Patent Office, under the reference number EP 4 338 267.
The patent is for SIRT6, which regulates DNA damage repair. Genflow's lead drug candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene.
Genflow is currently undertaking key investigational new drug-enabling development activities that will help define the pharmacological and toxicological properties of GF-1002 and its potential benefits, initially, for non-alcoholic steatohepatitis patients.
The patent is titled: "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," which Genflow said "enhances the understanding and potential treatment of diseases associated with ageing by focusing on the SIRT6 gene/protein, known for its critical role in DNA repair, metabolism, and longevity."
Genflow Chief Executive Officer Eric Leire said: "This approval from the European Patent Office highlights the innovative spirit of our collaborative team, and we are incredibly proud to be part of this pioneering research alongside such respected institutions." He continued, "This patent represents a leap forward in our understanding and capabilities in treating age-related conditions and marks a significant step forward in our mission to develop effective therapies for NASH and other age-related diseases."
Shares in Genflow were up 1.7% at 1.50 pence each in London on Thursday afternoon.
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Genflow Biosci (GENF)